Page last updated: 2024-11-05

benzyl cyanide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzyl cyanide: reversible monoamine oxidase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8794
CHEMBL ID3560735
CHEBI ID25979
SCHEMBL ID37831
MeSH IDM0049441

Synonyms (96)

Synonym
nsc3407
nsc-3407
alpha-tolunitrile
phenyl acetyl nitrile
CHEBI:25979 ,
omega-cyanotoluene
alpha-cyanotoluene
(cyanomethyl)benzene
phenylacetonitrile, liquid
wln: nc1r
.alpha.-cyanotoluene
benzyl cyanide
.omega.-cyanotoluene
benzeneacetonitrile
nsc118418
140-29-4
acetonitrile, phenyl-
benzyl nitrile
nsc-118418
phenylacetonitrile ,
2-phenylacetonitrile
toluene, .alpha.-cyano-
usaf kf-21
.alpha.-tolunitrile
inchi=1/c8h7n/c9-7-6-8-4-2-1-3-5-8/h1-5h,6h
phenyl-acetonitrile
NCGC00090854-01
un2470
benzylnitrile
nsc 118418
ccris 4698
hsdb 2103
benzylkyanid [czech]
ai3-04975
einecs 205-410-5
acetic acid, phenyl-nitrile
toluene, alpha-cyano-
phenylacetonitrile, liquid [un2470] [poison]
benzyl cyanide, 98%
benzyl cyanide, >=99%
ethyl2-fluoroacrylate
FT-0657342
P0128
AKOS000118943
2-phenylethanenitrile
A807640
NCGC00090854-02
dtxsid2021492 ,
NCGC00257771-01
cas-140-29-4
tox21_200217
dtxcid401492
2-phenyl-acetonitrile
23g40prp93 ,
phenylacetonitrile, liquid [un2470] [poison]
unii-23g40prp93
ec 205-410-5
benzylkyanid
triamterene impurity d [ep impurity]
benzyl cyanide [hsdb]
benzyl cyanide [mi]
SCHEMBL37831
alpha-phenylacetonitrile
phenylacteonitrile
benzene acetonitrile
benzene-acetonitrile
phenylacetonitile
benzylcyanide
phenyl acetonitrile
bncn
phenylacetonitrile-2,2-d2
un 2470
phenacetonitrile
CHEMBL3560735
J-519675
mfcd00001894
benzyl cyanide, analytical standard
benzyl-d7 cyanide, 98 atom % d
benzeneacetonitrile, 9ci
laquo omegaraquo -cyanotoluene
enzylcyanide
cyanophenylmethane
toluene, alpha -cyano-
alpha-cyano-toluene
alpha -cyano-
alpha -tolunitrile
alpha -cyanotoluene
phenylacetonitrile (benzyl cyanide)
benzyl cyanide-13c
benzyl-alpha-13c cyanide
milnacipran ep impurity e
phenylacetonitrile; (cyanomethyl)benzene; 2-phenylacetonitrile; 2-phenylethanenitrile; benzeneethanenitrile; benzyl nitrile
Q425620
STL199233
BB 0304017
triamterene impurity d (ep impurity)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Immunological studies showed that PAN significantly decreased the differential haemocyte counts (prohemocytes and plasmatocytes) with a dose-response relationship."( The aggregation pheromone phenylacetonitrile: Joint action with the entomopathogenic fungus Metarhizium anisopliae var. acridum and physiological and transcriptomic effects on Schistocerca gregaria nymphs.
Abdellaoui, K; Acheuk, F; Ben Hamouda, A; Boughattas, I; Hajji-Hedfi, L; Miladi, M; Mkhinini, M; Tlili, H, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
pheromoneA semiochemical used in olfactory communication between organisms of the same species eliciting a change in sexual or social behaviour.
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
aromatic glucosinolate activation19
prunasin and amygdalin biosynthesis015
prunasin and amygdalin biosynthesis115
aromatic glucosinolate activation111

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency0.24910.000714.592883.7951AID1259369
activating transcription factor 6Homo sapiens (human)Potency0.89130.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (8.77)18.7374
1990's1 (1.75)18.2507
2000's19 (33.33)29.6817
2010's25 (43.86)24.3611
2020's7 (12.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.26 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index5.98 (4.65)
Search Engine Demand Index87.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]